Drugs / Olorinab
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04655599 | Jan → Apr 2021 | irritable bowel syndrome | Arena Pharmaceuticals | Terminated | No outcome recorded Stop: Business |
| Phase 22 trials · 1 missed | ||||||
| Phase 2 | NCT04043455 | Jul 2019 → Apr 2021 | irritable bowel syndrome | Arena Pharmaceuticals | Terminated | Missed primary Stop: Business |
| Phase 2 | NCT03155945 | Jul 2017 → Sep 2018 | Crohn disease | Arena Pharmaceuticals | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Olorinab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04655599 ↗ |
| Known as | APD-371 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4175981 ↗ |
| Action | Activate | “a highly selective, full agonist of the cannabinoid receptor 2” PMID 33863856 ↗ Jan 20221“Cannabinoid CB2 receptor agonist” CHEMBL4175981 ↗ |
| Modality | Small molecule | — CHEMBL4175981 ↗ |
| Route | Oral | “Participants received olorinab 100 mg oral tablets TID for 8 weeks” NCT03155945 ↗ |
| Target | CNR2 | “Cannabinoid CB2 receptor agonist” CHEMBL4175981 ↗ |